AACR, Ramkumar et al

Share This Presentation

Mar 29 – Apr 3, 2019: Atlanta, Georgia

Poster presentation:
Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress

Share This Presentation

Latest News

News

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

News

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

AACR, Ramkumar et al

Share This Presentation

Share This Presentation

Latest News

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Subscribe to our newsletter

BerGenBio ASA

Key Information

Useful Information

Get In Touch

Share This Presentation

Share This Presentation

Latest News

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Subscribe to our newsletter

Footer

BerGenBio ASA

Key Information

Useful Information

Get In Touch